Short-chain fatty acids: the role in the development of irritable bowel syndrome

Main Article Content

Yu.M. Stepanov
I.Ya. Budzak
I.A. Klenina

Abstract

The article deals with the concepts of irritable bowel syndrome. A brief analysis of probable factors of irritable bowel syndrome development was performed. The role of intestinal microflora and the contribution of short-chain fatty acids to the processes occurring in the irritable bowel syndrosme are considered in detail. There were analyzed the studies of different authors concerning short-chain fatty acids. The results of own studies evaluating fecal content of short-chain fatty acids in patients with irritable bowel syndrome are shown. There was revealed a significant increase in the level of short-chain fatty acids, especially in diarrheal form of irritable bowel syndrome.

Article Details

How to Cite
Stepanov, Y., Budzak, I., & Klenina, I. (2009). Short-chain fatty acids: the role in the development of irritable bowel syndrome. GASTROENTEROLOGY, 53(1), 49–53. https://doi.org/10.22141/2308-2097.53.1.2019.163458
Section
Original Researches

References

Sood R, Gracie DJ, Law GR, Ford AC. Systematic review with meta-analysis: the accuracy of diagnosing irritable bowel syndrome with symptoms, biomarkers and/or psychological markers. Aliment Pharmacol Ther. 2015 Sep;42(5):491-503. doi: 10.1111/apt.13283. 

Tan J, McKenzie C, Potamitis M, Thorburn AN, Mackay CR, Macia L. The role of short-chain fatty acids in health and disease. Adv Immunol. 2014;121:91-119. doi: 10.1016/B978-0-12-800100-4.00003-9.

Vinolo MA, Rodrigues HG, Nachbar RT, Curi R. Regulation of Inflammation by Short Chain Fatty Acids. Nutrients. 2011 Oct;3(10):858-76. doi: 10.3390/nu3100858.

Kimura I. Host energy regulation via SCFAs receptors, as dietary nutrition sensors, by gut microbiota. Yakugaku Zasshi. 2014;134(10):1037-42. (in Japanese).

Hurst NR, Kendig DM, Murthy KS, Grider JR. The short chain fatty acids, butyrate and propionate, have differential effects on the motility of the guinea pig colon. Neurogastroenterol Motil. 2014 Nov;26(11):1586-96. doi: 10.1111/nmo.12425.

Natarajan N, Pluznick JL. From microbe to man: the role of microbial short chain fatty acid metabolites in host cell biology. Am J Physiol Cell Physiol. 2014 Dec 1;307(11):C979-85. doi: 10.1152/ajpcell.00228.2014.

Farup PG, Rudi K, Hestad K. Faecal short-chain fatty acids - a diagnostic biomarker for irritable bowel syndrome? BMC Gastroenterol. 2016 Apr 27;16(1):51. doi: 10.1186/s12876-016-0446-z.

Topping DL, Clifton PM.Short-chain fatty acids and human colonic function: roles of resistant starch and nonstarch polysaccharides. Physiol Rev. 2001 Jul;81(3):1031-64. doi: 10.1152/physrev.2001.81.3.1031.

Martin CR, Osadchiy V, Kalani A, Mayer EA. The Brain-Gut-Microbiome Axis. Cell Mol Gastroenterol Hepatol. 2018 Apr 12;6(2):133-148. doi: 10.1016/j.jcmgh.2018.04.003.

Tolhurst G, Heffron H, Lam YS, et al. Short-chain fatty acids stimulate glucagon-like peptide-1 secretion via the G-protein-coupled receptor FFAR2. Diabetes. 2012 Feb;61(2):364-71. doi: 10.2337/db11-1019.

O'Malley D. Endocrine regulation of gut function - a role for glucagon-like peptide-1 in the pathophysiology of irritable bowel syndrome. Exp Physiol. 2019 Jan;104(1):3-10. doi: 10.1113/EP087443.

De la Cuesta-Zuluaga J, Mueller NT, Álvarez-Quintero R, et al. Higher fecal short-chain fatty acid levels are associated with gut microbiome dysbiosis, obesity, hypertension and cardiometabolic disease risk factors. Nutrients. 2018 Dec 27;11(1). pii: E51. doi: 10.3390/nu11010051.

Rau M, Rehman A, Dittrich M, et al. Fecal SCFAs and SCFA-producing bacteria in gut microbiome of human NAFLD as a putative link to systemic T-cell activation and advanced disease. United European Gastroenterol J. 2018 Dec;6(10):1496-1507. doi: 10.1177/2050640618804444.

O'Hara AM, Shanahan F. The gut flora as a forgotten organ. EMBO Rep. 2006 Jul;7(7):688-93. doi: 10.1038/sj.embor.7400731.

Ghoshal UC, Shukla R, Ghoshal U, Gwee KA, Ng SC, Quigley EM. The gut microbiota and irritable bowel syndrome: friend or foe? Int J Inflam. 2012;2012:151085. doi: 10.1155/2012/151085.

Brint EK, MacSharry J, Fanning A, Shanahan F, Quigley EM. Differential expression of toll-like receptors in patients with irritable bowel syndrome. Am J Gastroenterol. 2011 Feb;106(2):329-36. doi: 10.1038/ajg.2010.438.

Barbara G, Zecchi L, Barbaro R, et al. Mucosal permeability and immune activation as potential therapeutic targets of probiotics in irritable bowel syndrome. J Clin Gastroenterol. 2012 Oct;46 Suppl:S52-5. doi: 10.1097/MCG.0b013e318264e918.

Simrén M, Barbara G, Flint HJ, et al. Intestinal microbiota in functional bowel disorders: a Rome foundation report. Gut. 2013 Jan;62(1):159-76. doi: 10.1136/gutjnl-2012-302167.

Verdu EF, Bercik P, Verma-Gandhu M, et al. Specific probiotic therapy attenuates antibiotic induced visceral hypersensitivity in mice. Gut. 2006 Feb;55(2):182-90. doi: 10.1136/gut.2005.066100.

Zhao G, Nyman M, Jönsson JA. Rapid determination of short-chain fatty acids in colonic contents and faeces of humans and rats by acidified water-extraction and direct-injection gas chromatography. Biomed Chromatogr. 2006 Aug;20(8):674-82. doi: 10.1002/bmc.580.

Most read articles by the same author(s)

1 2 3 4 5 6 7 8 9 10 11 > >>